Literature DB >> 1794257

The scleroderma-like syndrome of insulin-dependent diabetes mellitus.

R Brik1, M Berant, P Vardi.   

Abstract

The scleroderma-like syndrome (SLS) of diabetes consists of limited joint mobility and digital sclerosis. It is described in 8-50% of insulin-dependent diabetes mellitus patients and is the earliest clinically apparent long-term complication of diabetes in children and adolescents. The frequency of this finding appears to be related to the duration of diabetes and increasing age. Less clear are the relationships between this syndrome and glycaemic control or genetic factors. SLS is an easily identifiable marker for those young patients who may be at increased risk for the development of early microvascular complications. Recognition of this characterization will permit the clinician to focus on newer and improved techniques for long-term physiological control of the diabetes, in an attempt to prevent microvascular disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1794257

Source DB:  PubMed          Journal:  Diabetes Metab Rev        ISSN: 0742-4221


  4 in total

1.  Relationship Between Skin Intrinsic Fluorescence--an Indicator of Advanced Glycation End Products-and Upper Extremity Impairments in Individuals With Diabetes Mellitus.

Authors:  Kshamata M Shah; B Ruth Clark; Janet B McGill; Catherine E Lang; John Maynard; Michael J Mueller
Journal:  Phys Ther       Date:  2015-04-09

2.  Shoulder limited joint mobility in people with diabetes mellitus.

Authors:  Kshamata M Shah; B Ruth Clark; Janet B McGill; Catherine E Lang; Michael J Mueller
Journal:  Clin Biomech (Bristol, Avon)       Date:  2015-01-06       Impact factor: 2.063

Review 3.  Dermatologic conditions associated with diabetes.

Authors:  Karen Nern
Journal:  Curr Diab Rep       Date:  2002-02       Impact factor: 4.810

4.  Peripheral neuropathy: a complication of systemic sclerosis.

Authors:  Tracy M Frech; Gordon Smith; Melissa Reily; James Chamberlain; Maureen A Murtaugh; Jason Penrod; Michael J Battistone; Barry M Stults
Journal:  Clin Rheumatol       Date:  2013-02-13       Impact factor: 2.980

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.